InvestorsObserver
Sign Up Login

ARDS Aridis Pharmaceuticals Inc

$0.07 $0.01 (8.33%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

ARDS Stock Analysis Overview

What this means: Aridis Pharmaceuticals Inc (ARDS) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives ARDS a rank of 15. Our methodology considers analysis of the company's financial situation and how it has traded recently. ARDS rank of 15 means that it ranks below 85% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

ARDS Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

ARDS Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

ARDS Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

ARDS Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

ARDS Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

ARDS Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

ARDS Stock Analysis Overview

What this means: Aridis Pharmaceuticals Inc (ARDS) gets a very poor rank from InvestorsObserver. Our comprehensive analysis of fundamental and technical factors gives ARDS a rank of 15. Our methodology considers analysis of the company's financial situation and how it has traded recently. ARDS rank of 15 means that it ranks below 85% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full ARDS report

ARDS Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

ARDS Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

ARDS Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

ARDS Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

ARDS Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

ARDS Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Aridis Pharmaceuticals Inc (ARDS) Analyst Forecast

ARDS Price, Volume, Earnings, and Dividend Date

  • Last Price $0.07
  • Previous Close $0.06
  • Change $0.01
  • Open $0.06
  • Volume 24,355
  • Avg. Volume (100-day) 117,287
  • Market Cap 2,897,311
  • Days Range 0.0581 - 0.065
  • 52-week Range 0.05 - 0.54
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 09/06/23
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.573
  • PEG Ratio —

Aridis Pharmaceuticals Inc (ARDS) Company Description

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

Aridis Pharmaceuticals Inc (ARDS) Stock Chart

View Interactive ARDS chart

My Watchlists

Top Stocks in Biotechnology